Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Somatostatin analogs have 2 roles: treating symptoms related to gastroenteropancreatic neuroendocrine tumors (GEP-NETS) and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
TranscriptHow have somatostatin analogs enhanced the treatment landscape of gastroenteropancreatic neuroendocrine tumors?
So, somatostatin analogs are extremely important. They have 2 roles. They have the role to treat symptoms related to these tumors because many of these tumors will secrete hormones, and we can control some of that with the use of somatostatin analogs. But, it’s also very important as a treatment in terms of controlling tumor growth. We know from the CLARINET and the PROMID trials that the use of somatostatin analogs as first-line treatment in the metastatic setting or in patients with locally advanced disease delays tumor growth of these tumors.
So, it’s extremely fundamental for the treatment landscape of neuroendocrine tumors, the use of somatostatin analogs.
How does sequential treatment with these therapies impact clinical outcomes?
We typically use somatostatin analogs as the first line for patients, and the general consensus in the neuroendocrine tumors field is that they are very interchangeable. So, you start with one, and then when you progress, you should change classes of treatment. However, there is some interesting new data, a retrospective analysis coming out and saying that perhaps there might be a role to switching somatostatin analogs before jumping to a completely different class of therapies.
We truly don’t know that, so for the time being, so we typically will use 1 of the 2 commercially available somatostatin analogs as the first line, and then at the time of progression, if you’re just doing it for tumor control and patients don’t have any symptoms, then you will switch to a completely different class of treatment or intervention. But, I’m very interested in this new data coming out that perhaps there might be a role of sequention with somatostatin analogs. It’s too early to tell, but we’ll see when more studies come out.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More